Objective: To determine compliance and improvement in sustained viral response (SVR) by following response guided therapy (RGT) plan of interferon and ribavirin, for genotype 3 in chronic hepatitis C. Methods: Patients with chronic hepatitis C genotype 3, who were eligible for interferon-ribavirin therapy and consented for RGT, were included. Those with no rapid viral response (RVR), having coarse echotexture of liver or undergoing re-treatment, were advised 48 week treatment whereas, rest had 24 week standard therapy. PCR for HCV RNA checked 6 months after discontinuing treatment, was the primary end point of study. Results: Of 154 patients, included in the study with mean age of 39. 9 (±10. 84) and male to female ratio 1. 4/1 (94/60), majority of patients, 136 (88. 4%) were treatment naïve whereas, 18 (11. 6%) were being retreated. On ultrasound, 63 (40. 9%) patients had coarse liver and 33 (21. 4%) had splenomegaly. RVR was achieved in 99 (64. 3%) patients. Overall 66(42. 8%) patients merited extended duration of therapy as per RGT plan but only 22 (33%) were compliant. Treatment related side effects were the dominant reason for declining RGT in 33 (75%) patients. SVR was noted in 111 (72. 1%) patients. Those patients with extended therapy (RGT), had SVR 90. 9% (20/22), although, better but statistically not significant than those who stopped therapy at 6 months 77. 2% (34/44) (p value 0. 11). Conclusion: Response guided therapy plan did not improve SVR to pegylatedinterferon and ribavirin therapy in patients with genotype 3 and it has low patient compliance due to treatment related side effects.